Fri, Aug 29, 2014, 4:18 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

AcelRx Pharmaceuticals, Inc. (ACRX) Message Board

  • transitionalximes transitionalximes Dec 4, 2012 6:05 PM Flag

    sec filing states phase 3 results Delayed until Q1 2013 in Prospectus filing

    sec filing states phase 3 results Delayed until Q1 2013 in Prospectus filing

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • It was always 1q 2103 No suprise

    • Page 1 in the sec filing . Table of contents.
      " In November 2012, we reported top-line data showing that the primary endpoint of non-inferiority was met in an open-label active-comparator Phase 3 trial for our lead product candidate, the NanoTab System. We are also conducting two placebo-controlled efficacy and safety Phase 3 clinical trials for the NanoTab System, the first trial in patients with post-operative pain following open-abdominal surgery and the second trial in patients with post-operative pain following hip and knee replacement surgeries. We expect top-line data from both placebo-controlled efficacy and safety Phase 3 trials in the first quarter of 2013."

      Sentiment: Strong Buy

      • 1 Reply to transitionalximes
      • Public offerring just released . Up to 11.5 million shares to be sold. Re; Page 1 in the sec filing .
        Table of contents.
        " In November 2012, we reported top-line data showing that the primary endpoint of non-inferiority was met in an open-label active-comparator Phase 3 trial for our lead product candidate, the NanoTab System. We are also conducting two placebo-controlled efficacy and safety Phase 3 clinical trials for the NanoTab System, the first trial in patients with post-operative pain following open-abdominal surgery and the second trial in patients with post-operative pain following hip and knee replacement surgeries. We expect top-line data from both placebo-controlled efficacy and safety Phase 3 trials in the first quarter of 2013."

        Sentiment: Buy

 
ACRX
7.15+0.03(+0.42%)4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.